Skip to content
Axcess News – Lifestyle
Author:
Alpha Tau Medical Ltd.
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16
November 15, 2026
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
November 12, 2026
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
October 29, 2026
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
October 22, 2026
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
October 19, 2026
Alpha Tau to Participate in October Investor Conferences
October 5, 2026
Alpha Tau to Participate in September Investor Conferences
September 2, 2026
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
August 10, 2026
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Specified Threshold for Success
July 21, 2026
1
2
Next Page
→